These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 10209528)

  • 1. [Intermittent therapy ought to strengthen the immune system].
    Volkert R
    Dtsch Med Wochenschr; 1999 Mar; 124(11):A8. PubMed ID: 10209528
    [No Abstract]   [Full Text] [Related]  

  • 2. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.
    Emini EA; Koff WC
    Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131
    [No Abstract]   [Full Text] [Related]  

  • 3. Immune control of HIV-1 after early treatment of acute infection.
    Rosenberg ES; Altfeld M; Poon SH; Phillips MN; Wilkes BM; Eldridge RL; Robbins GK; D'Aquila RT; Goulder PJ; Walker BD
    Nature; 2000 Sep; 407(6803):523-6. PubMed ID: 11029005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can immune systems be trained to fight HIV?
    Balter M
    Science; 1999 Nov; 286(5444):1470-11. PubMed ID: 10610544
    [No Abstract]   [Full Text] [Related]  

  • 5. Public health. A sound rationale needed for phase III HIV-1 vaccine trials.
    Burton DR; Desrosiers RC; Doms RW; Feinberg MB; Gallo RC; Hahn B; Hoxie JA; Hunter E; Korber B; Landay A; Lederman MM; Lieberman J; McCune JM; Moore JP; Nathanson N; Picker L; Richman D; Rinaldo C; Stevenson M; Watkins DI; Wolinsky SM; Zack JA
    Science; 2004 Jan; 303(5656):316. PubMed ID: 14726576
    [No Abstract]   [Full Text] [Related]  

  • 6. Towards the development of a therapeutic vaccine for the treatment of HIV-1 infection: are we closer than ever?
    Egan MA
    Expert Rev Vaccines; 2007 Jun; 6(3):289-91. PubMed ID: 17542741
    [No Abstract]   [Full Text] [Related]  

  • 7. Can the body control HIV infection without drugs?
    Check E
    Newsweek; 2000 Oct; 136(15):59. PubMed ID: 11184537
    [No Abstract]   [Full Text] [Related]  

  • 8. No differences in cellular immune responses between asymptomatic HIV type 1- and type 2-infected Gambian patients.
    Jaye A; Sarge-Njie R; Schim van der Loeff M; Todd J; Alabi A; Sabally S; Corrah T; Whittle H
    J Infect Dis; 2004 Feb; 189(3):498-505. PubMed ID: 14745708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can immune responses to human immunodeficiency virus be preserved, enhanced, or restored?
    Walker BD
    AIDS Clin Rev; 2000-2001; ():101-14. PubMed ID: 10999218
    [No Abstract]   [Full Text] [Related]  

  • 10. Bad Boys question received wisdom on HIV.
    Check E
    Nature; 2006 Sep; 443(7110):380-1. PubMed ID: 17006482
    [No Abstract]   [Full Text] [Related]  

  • 11. HIV: Bad news for stop--start therapy?
    McMichael AJ; Rowland-Jones SL
    Nature; 2002 Nov; 420(6914):371, 373. PubMed ID: 12459769
    [No Abstract]   [Full Text] [Related]  

  • 12. [HIV: interleukin 2 supports the immune system].
    Moser-Jünemann C; Jäger H
    MMW Fortschr Med; 1999 Dec; 141(49-50):24. PubMed ID: 10726142
    [No Abstract]   [Full Text] [Related]  

  • 13. HIV type 1-specific helper T cells: a critical host defense.
    Rosenberg ES; Walker BD
    AIDS Res Hum Retroviruses; 1998 Jun; 14 Suppl 2():S143-7. PubMed ID: 9672231
    [No Abstract]   [Full Text] [Related]  

  • 14. HIV/AIDS vaccines: 2007.
    Robinson HL
    Clin Pharmacol Ther; 2007 Dec; 82(6):686-93. PubMed ID: 17971817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1-specific CD8(+) T cells do not correlate with viral load in HIV-1-positive patients.
    Bartovská Z; Beran O; Rozsypal H; Holub M
    Acta Virol; 2007; 51(1):59-61. PubMed ID: 17432946
    [No Abstract]   [Full Text] [Related]  

  • 16. A boost for the immune system.
    TreatmentUpdate; 1998 Nov; 10(9):3-4. PubMed ID: 11365925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human immunodeficiency virus pathogenesis and prospects for immune control in patients with established infection.
    Cohen DE; Walker BD
    Clin Infect Dis; 2001 Jun; 32(12):1756-68. PubMed ID: 11360218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression.
    Angel JB; Parato KG; Kumar A; Kravcik S; Badley AD; Fex C; Ashby D; Sun E; Cameron DW
    J Infect Dis; 2001 Feb; 183(4):546-54. PubMed ID: 11170979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CTL escape and increased viremia irrespective of HIV-specific CD4+ T-helper responses in two HIV-infected individuals.
    Geels MJ; Jansen CA; Baan E; De Cuyper IM; van Schijndel GJ; Schuitemaker H; Goudsmit J; Pollakis G; Miedema F; Paxton WA; van Baarle D
    Virology; 2006 Feb; 345(1):209-19. PubMed ID: 16246391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV).
    Boström AC; Hejdeman B; Matsuda R; Fredriksson M; Fredriksson EL; Bratt G; Sandström E; Wahren B
    Vaccine; 2004 Apr; 22(13-14):1683-91. PubMed ID: 15068851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.